ClinicalTrials.gg
TerminatedNCT02780700Updated Feb 3, 2025Results posted

Nintedanib Alone or in Combination With Capecitabine in Refractory Metastatic Colorectal Cancer [LUME-Colon 2]

A Phase 2 interventional study of Nintedanib and Capecitabine in Colorectal Neoplasms, sponsored by Boehringer Ingelheim. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-03.

Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment

Why this study was terminated
Substance discontinued

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
1
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies in Colorectal Neoplasms by Boehringer Ingelheim — 1 open to participants now, 2 under way, none of them phase 3. Colorectal Neoplasms · Boehringer Ingelheim.

Enrollment
14th of 14
1 · median 57
Started
2016
with 1 other
Phase 2
5 of 14
none open now
Registered
7th of 14
by date

Among the 14 studies in Colorectal Neoplasms by Boehringer Ingelheim, this one is the 14th largest by enrollment, is one of 2 that started in 2016, is one of 5 in phase 2, and was the 7th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

1 of the 14 studies in Colorectal Neoplasms by Boehringer Ingelheim is open now, in 10 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 1,181 Colorectal Neoplasms studies recruiting now, 764 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Colorectal Neoplasms by Boehringer Ingelheim, or all of them as a file.
02

Study summary

The objective of this Phase II study is to assess the efficacy and safety of nintedanib alone or in combination with capecitabine for patients with refractory metastatic colorectal cancer (mCRC) after failure of at least 2 lines of standard treatment

03

Conditions studied

  • Colorectal Neoplasms
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed colorectal adenocarcinoma
  • or locally advanced disease not amenable to curative surgery and/or radiotherapy
  • (ECOG) performance status \<= 1
  • At least one according to 1.1
  • Previously treated with all of the following: fluoropyrimidine, (e.g. 5-fluorouracil (5-FU), capecitabine or TAS-102); oxaliplatin: Patients treated with oxaliplatin in setting should have progressed within 6 months of completion of adjuvant therapy or they must have been treated with oxaliplatin for metastatic disease; Irinotecan; Vascular Endothelial Growth Factor (VEGF) directed treatment (e.g. bevacizumab, aflibercept, ramucirumab or regorafenib); cetuximab or panitumumab for patients with K-Ras wt or Ras wt tumors
  • Minimal time interval of 3 weeks between the last administration of Colorectal Cancer (CRC) treatment (cytotoxics or targeted agents) and starting of trial therapy
  • Adequate liver and kidney function
  • Further inclusion criteria apply

Exclusion criteria

Exclusion criteria:

  • Prior treatment with nintedanib.
  • Any other agent received within 3 weeks prior to randomization
  • Known or intolerability to the trial drugs or their
  • History of other in the last 5 years, in particular those that could interfere with interpretation of results. Patients with adequately treated basal or squamous cell skin cancer or cervix carcinoma and other early stage cancer treated curatively are eligible
  • History of severe or unexpected reactions to fluoropyrimidine therapy or any of its excipients
  • Known dihydropyrimidine dehydrogenase (DPD) deficiency
  • Treatment with sorivudine or its chemically related analogues, such as brivudine
  • Serious concomitant disease or medical condition affecting compliance with trial requirements or which are considered relevant for the evaluation of the efficacy or safety of the trial drug, such as neurologic, psychiatric, infectious disease or active ulcers (gastro-intestinal tract, skin) or laboratory abnormality that may increase the risk associated with trial participation or trial drug administration, and in the judgment of the investigator would make the patient inappropriate for entry into the trial
  • Major injuries and/or surgery or bone fracture within 4 weeks of trial inclusion (signing ), or planned surgical procedures during the trial period
  • Significant cardiovascular diseases (i.e. uncontrolled hypertension, unstable angina, history of myocardial infarction within past 6 months of trial inclusion, congestive heart failure > (NYHA) II)
  • History of severe hemorrhagic or thromboembolic event in the past 6 months (excluding central venous catheter thrombosis and peripheral deep vein thrombosis). Known inherited predisposition to bleeding or to thrombosis
  • Bleeding or thrombotic disorders requiring anticoagulant therapy such as warfarin, or similar agents requiring therapeuticInternational normalized ratio () monitoring (treatment with low molecular weight heparin and/or heparin flush as needed for maintenance of an indwelling intravenous device is allowed)
  • Inflammatory bowel disease and other serious medical conditions increasing the risk of perforation or bleeding according to investigator's judgment
  • Gastrointestinal disorders or abnormalities that would interfere with absorption of study drug
  • Patient with that are symptomatic and/or require therapy. Patients with previously treated and stable brain metastases are allowed
  • Further exclusion criteria apply
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1 participant (actual)

Study arms

  • Experimental
    Nintedanib

    Drug: Nintedanib

  • Experimental
    Nintedanib plus capecitabine

    Drug: Nintedanib · Drug: Capecitabine

Interventions

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS)

    PFS is defined as the time from randomization until objective tumor progression or death. Since only one patient was enrolled prior to termination of the trial, no data summarization or analysis was carried out.

    Time frame: Data collected up to cut-off date 09 Sep 2016, Up to 02 months

Secondary outcomes

  1. Overall Survival (OS)

    Overall survival is defined as the time from randomization until death from any cause. Since only one patient was enrolled prior to termination of the trial, no data summarization or analysis was carried out.

    Time frame: Data collected up to cut-off date 09 Sep 2016, Up to 02 months

  2. Objective Response Rate (ORR)

    ORR is defined as complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Since only one patient was enrolled prior to termination of the trial, no data summarization or analysis was carried out.

    Time frame: tumor response was to be assessed by imaging according to RECIST (version 1.1) every 6 weeks.

  3. Disease Control (DC)

    Disease control is defined as CR or PR or Stable disease (SD) per RECIST version 1.1. Since only one patient was enrolled prior to termination of the trial, no data summarization or analysis was carried out.

    Time frame: Data collected up to cut-off date 09 Sep 2016, Up to 02 months

  4. Percentage of Patients With Grade 3 or Worse Adverse Events

    Percentage of patients with grade 3 or worse adverse events.

    Time frame: Data collected up to cut-off date 09 Sep 2016, Up to 02 months

07

Results

Posted Oct 11, 2018
Limitations and caveats
Trial was terminated prematurely because it was determined that nintedanib monotherapy demonstrated lack of efficacy in this indication in pivotal Phase III trial (LUME-Colon 1) that was ongoing at the time of the initiation of this trial.

Participant flow

This was an exploratory, phase II multi-center, non-comparative, open-label, randomized trial to assess the efficacy and safety of nintedanib alone, or in combination with capecitabine in patients with refractory metastatic colorectal cancer.

Participant flow — Overall Study
MilestoneNintedanib Plus Capecitabine
Started1
Completed0
Not completed1
Withdrew: Progressive disease1

Outcome measures

PrimaryProgression Free Survival (PFS)

PFS is defined as the time from randomization until objective tumor progression or death. Since only one patient was enrolled prior to termination of the trial, no data summarization or analysis was carried out.

Time frame:
Data collected up to cut-off date 09 Sep 2016, Up to 02 months
Reported as:
Median · months
Progression Free Survival (PFS)
monthsNintedanib Plus Capecitabine
Progression Free Survival (PFS)NA (NA to NA)
SecondaryOverall Survival (OS)

Overall survival is defined as the time from randomization until death from any cause. Since only one patient was enrolled prior to termination of the trial, no data summarization or analysis was carried out.

Time frame:
Data collected up to cut-off date 09 Sep 2016, Up to 02 months
Reported as:
Median · months
Overall Survival (OS)
monthsNintedanib Plus Capecitabine
Overall Survival (OS)NA (NA to NA)
SecondaryObjective Response Rate (ORR)

ORR is defined as complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Since only one patient was enrolled prior to termination of the trial, no data summarization or analysis was carried out.

Time frame:
tumor response was to be assessed by imaging according to RECIST (version 1.1) every 6 weeks.
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR)
Percentage of participantsNintedanib Plus Capecitabine
Objective Response Rate (ORR)NA
SecondaryDisease Control (DC)

Disease control is defined as CR or PR or Stable disease (SD) per RECIST version 1.1. Since only one patient was enrolled prior to termination of the trial, no data summarization or analysis was carried out.

Time frame:
Data collected up to cut-off date 09 Sep 2016, Up to 02 months
Reported as:
Number · Percentage of participants
Disease Control (DC)
Percentage of participantsNintedanib Plus Capecitabine
Disease Control (DC)NA
SecondaryPercentage of Patients With Grade 3 or Worse Adverse Events

Percentage of patients with grade 3 or worse adverse events.

Time frame:
Data collected up to cut-off date 09 Sep 2016, Up to 02 months
Reported as:
Number · Percentage of participants
Percentage of Patients With Grade 3 or Worse Adverse Events
Percentage of participantsNintedanib Plus Capecitabine
Percentage of Patients With Grade 3 or Worse Adverse Events0

Adverse events

Collected over From first drug administration till end of trial; up to 3 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nintedanib Plus Capecitabine0/1 (0%)0/1 (0%)1/1 (100%)
Most frequent other events
Most frequent other events
EventNintedanib Plus Capecitabine
Decreased appetiteMetabolism and nutrition disorders1/1
FatigueGeneral disorders1/1

Baseline characteristics

Treated set (TS): This will comprise all patients who are randomized and are documented to have taken at least one dose of trial medication

Age, Continuous
Age, Continuous(years)Nintedanib Plus Capecitabine
Mean50 ± NA
Sex: Female, Male
Sex: Female, Male(Participants)Nintedanib Plus Capecitabine
Female1
Male0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Nintedanib Plus Capecitabine
Hispanic or Latino1
Not Hispanic or Latino0
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Nintedanib Plus Capecitabine
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White1
More than one race0
Unknown or Not Reported0
08

Study locations

1 site
  • Fort Wayne Medical Oncology Hematology
    Fort Wayne, Indiana 46845, United States
09

References and documents

Related links

Individual participant data

Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.mystudywindow.com/msw/datatransparency

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2016, a primary completion of Sep 2016 and a completion of Sep 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2018, 2 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2016
First posted
May 23, 2016
Start
Jul 5, 2016
Primary completionActual
Sep 9, 2016
CompletionActual
Sep 9, 2016
Results first posted
Oct 11, 2018
Last update
Feb 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02780700
Responsible party
Sponsor
First posted
May 23, 2016
Start date
Jul 5, 2016
Primary completion
Sep 9, 2016
Completion
Sep 9, 2016
Results posted
Oct 11, 2018
Last update
Feb 3, 2025

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nintedanib

Start the discussion